{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:40:27Z","timestamp":1793724027750,"version":"4.6.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"33","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372768"],"award-info":[{"award-number":["82372768"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U23A20401"],"award-info":[{"award-number":["U23A20401"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82422014"],"award-info":[{"award-number":["82422014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Commission","doi-asserted-by":"publisher","award":["JCYJ20240813145421029"],"award-info":[{"award-number":["JCYJ20240813145421029"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.1038\/s41388-026-03866-x","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:53:57Z","timestamp":1783518837000},"page":"3385-3400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PTP4A3 dephosphorylates EGFR to promote metastasis and enhance sensitivity to lapatinib in hepatocellular carcinoma"],"prefix":"10.1038","volume":"45","author":[{"given":"Yuyang","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyan","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangzhan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingsong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenfen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4525-5205","authenticated-orcid":false,"given":"Xijun","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3222-8715","authenticated-orcid":false,"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-4190","authenticated-orcid":false,"given":"Jia","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1146-5578","authenticated-orcid":false,"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"3866_CR1","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","volume":"141","author":"MA Lemmon","year":"2010","unstructured":"Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117\u201334.","journal-title":"Cell"},{"key":"3866_CR2","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.3390\/cancers7030860","volume":"7","author":"T Regad","year":"2015","unstructured":"Regad T. Targeting RTK signaling pathways in cancer. Cancers. 2015;7:1758\u201384.","journal-title":"Cancers"},{"key":"3866_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188391","volume":"1874","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Zhang YN, Wang KT, Chen L. Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy. Biochim Biophys Acta Rev Cancer. 2020;1874:188391.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3866_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.","journal-title":"Nat Rev Dis Primers"},{"key":"3866_CR5","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1592\/phco.22.15.1249.33482","volume":"22","author":"VK Pindolia","year":"2002","unstructured":"Pindolia VK, Zarowitz BJ. Imatinib mesylate, the first molecularly targeted gene suppressor. Pharmacotherapy. 2002;22:1249\u201365.","journal-title":"Pharmacotherapy"},{"key":"3866_CR6","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1158\/1078-0432.CCR-16-0934","volume":"23","author":"LR Bollu","year":"2017","unstructured":"Bollu LR, Mazumdar A, Savage MI, Brown PH. Molecular pathways: targeting protein tyrosine phosphatases in cancer. Clin Cancer Res. 2017;23:2136\u201342.","journal-title":"Clin Cancer Res"},{"key":"3866_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0079-6603(06)81008-1","volume":"81","author":"T Motiwala","year":"2006","unstructured":"Motiwala T, Jacob ST. Role of protein tyrosine phosphatases in cancer. Prog Nucleic Acid Res Mol Biol. 2006;81:297\u2013329.","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"3866_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188562","volume":"1876","author":"PP Gao","year":"2021","unstructured":"Gao PP, Qi XW, Sun N, Sun YY, Zhang Y, Tan XN, et al. The emerging roles of dual-specificity phosphatases and their specific characteristics in human cancer. Biochim Biophys Acta Rev Cancer. 2021;1876:188562.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3866_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10555-008-9121-3","volume":"27","author":"DC Bessette","year":"2008","unstructured":"Bessette DC, Qiu D, Pallen CJ. PRL PTPs: mediators and markers of cancer progression. Cancer Metastasis Rev. 2008;27:231\u201352.","journal-title":"Cancer Metastasis Rev"},{"key":"3866_CR10","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1517\/14728222.2014.892926","volume":"18","author":"AM Campbell","year":"2014","unstructured":"Campbell AM, Zhang ZY. Phosphatase of regenerating liver: a novel target for cancer therapy. Expert Opin Ther Targets. 2014;18:555\u201369.","journal-title":"Expert Opin Ther Targets"},{"key":"3866_CR11","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1158\/1535-7163.MCT-05-0248","volume":"4","author":"BJ Stephens","year":"2005","unstructured":"Stephens BJ, Han HY, Gokhale V, Von Hoff DD. PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther. 2005;4:1653\u201361.","journal-title":"Mol Cancer Ther"},{"key":"3866_CR12","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4161\/cbt.3.10.1111","volume":"3","author":"K Guo","year":"2004","unstructured":"Guo K, Li J, Tang JP, Koh V, Gan BQ, Zeng Q. Catalytic domain of PRL-3 plays an essential role in tumor metastasis: formation of PRL-3 tumors inside the blood vessels. Cancer Biol Ther. 2004;3:945\u201351.","journal-title":"Cancer Biol Ther"},{"key":"3866_CR13","doi-asserted-by":"publisher","first-page":"8959","DOI":"10.1158\/0008-5472.CAN-10-2041","volume":"70","author":"S Hardy","year":"2010","unstructured":"Hardy S, Wong NN, Muller WJ, Park M, Tremblay ML. Overexpression of the protein tyrosine phosphatase PRL-2 correlates with breast tumor formation and progression. Cancer Res. 2010;70:8959\u201367.","journal-title":"Cancer Res"},{"key":"3866_CR14","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/S0002-9440(10)63763-7","volume":"164","author":"X Wu","year":"2004","unstructured":"Wu X, Zeng H, Zhang X, Zhao Y, Sha H, Ge X, et al. Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells. Am J Pathol. 2004;164:2039\u201354.","journal-title":"Am J Pathol"},{"key":"3866_CR15","first-page":"2716","volume":"63","author":"Q Zeng","year":"2003","unstructured":"Zeng Q, Dong JM, Guo K, Li J, Tan HX, Koh V, et al. PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res. 2003;63:2716\u201322.","journal-title":"Cancer Res"},{"key":"3866_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1158\/0008-5472.CAN-10-1487","volume":"71","author":"YJ Jiang","year":"2011","unstructured":"Jiang YJ, Liu XQ, Rajput A, Geng LY, Ongchin M, Zeng Q, et al. Phosphatase PRL-3 is a direct regulatory target of TGF beta in colon cancer metastasis. Cancer Res. 2011;71:234\u201344.","journal-title":"Cancer Res"},{"key":"3866_CR17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.molcel.2008.04.002","volume":"30","author":"S Basak","year":"2008","unstructured":"Basak S, Jacobs SB, Krieg AJ, Pathak N, Zeng Q, Kaldis P, et al. The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation. Mol Cell. 2008;30:303\u201314.","journal-title":"Mol Cell"},{"key":"3866_CR18","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1158\/0008-5472.CAN-06-3598","volume":"67","author":"H Wang","year":"2007","unstructured":"Wang H, Quah SY, Dong JM, Manser E, Tang JP, Zeng Q. PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition. Cancer Res. 2007;67:2922\u20136.","journal-title":"Cancer Res"},{"key":"3866_CR19","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1074\/jbc.M608940200","volume":"282","author":"F Liang","year":"2007","unstructured":"Liang F, Liang J, Wang WQ, Sun JP, Udho E, Zhang ZY. PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. J Biol Chem. 2007;282:5413\u20139.","journal-title":"J Biol Chem"},{"key":"3866_CR20","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1158\/0008-5472.CAN-05-3116","volume":"66","author":"JJ Fiordalisi","year":"2006","unstructured":"Fiordalisi JJ, Keller PJ, Cox AD. PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Res. 2006;66:3153\u201361.","journal-title":"Cancer Res"},{"key":"3866_CR21","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.7150\/thno.22699","volume":"8","author":"N Mu","year":"2018","unstructured":"Mu N, Gu J, Liu N, Xue X, Shu Z, Zhang K, et al. PRL-3 is a potential glioblastoma prognostic marker and promotes glioblastoma progression by enhancing MMP7 through the ERK and JNK pathways. Theranostics. 2018;8:1527\u201339.","journal-title":"Theranostics"},{"key":"3866_CR22","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/emmm.201202183","volume":"5","author":"JE Park","year":"2013","unstructured":"Park JE, Yuen HF, Zhou JB, Al-Aidaroos AQ, Guo K, Valk PJ, et al. Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia. EMBO Mol Med. 2013;5:1351\u201366.","journal-title":"EMBO Mol Med"},{"key":"3866_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.bbrc.2006.01.102","volume":"342","author":"L Peng","year":"2006","unstructured":"Peng L, Jin G, Wang L, Guo J, Meng L, Shou C. Identification of integrin alpha1 as an interacting protein of protein tyrosine phosphatase PRL-3. Biochem Biophys Res Commun. 2006;342:179\u201383.","journal-title":"Biochem Biophys Res Commun"},{"key":"3866_CR24","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.bbamcr.2007.11.004","volume":"1783","author":"E Forte","year":"2008","unstructured":"Forte E, Orsatti L, Talamo F, Barbato G, De Francesco R, Tomei L. Ezrin is a specific and direct target of protein tyrosine phosphatase PRL-3. Biochim Biophys Acta. 2008;1783:334\u201344.","journal-title":"Biochim Biophys Acta"},{"key":"3866_CR25","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ijc.24111","volume":"124","author":"E Mizuuchi","year":"2009","unstructured":"Mizuuchi E, Semba S, Kodama Y, Yokozaki H. Down-modulation of keratin 8 phosphorylation levels by PRL-3 contributes to colorectal carcinoma progression. Int J Cancer. 2009;124:1802\u201310.","journal-title":"Int J Cancer"},{"key":"3866_CR26","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1002\/elps.200800780","volume":"30","author":"L Orsatti","year":"2009","unstructured":"Orsatti L, Forte E, Tomei L, Caterino M, Pessi A, Talamo F. 2-D Difference in gel electrophoresis combined with Pro-Q Diamond staining: a successful approach for the identification of kinase\/phosphatase targets. Electrophoresis. 2009;30:2469\u201376.","journal-title":"Electrophoresis"},{"key":"3866_CR27","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.1021\/pr100712t","volume":"9","author":"P Zheng","year":"2010","unstructured":"Zheng P, Liu YX, Chen L, Liu XH, Xiao ZQ, Zhao L, et al. Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer. J Proteome Res. 2010;9:4897\u2013905.","journal-title":"J Proteome Res"},{"key":"3866_CR28","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1111\/j.1349-7006.2010.01651.x","volume":"101","author":"S Semba","year":"2010","unstructured":"Semba S, Mizuuchi E, Yokozaki H. Requirement of phosphatase of regenerating liver-3 for the nucleolar localization of nucleolin during the progression of colorectal carcinoma. Cancer Sci. 2010;101:2254\u201361.","journal-title":"Cancer Sci"},{"key":"3866_CR29","doi-asserted-by":"publisher","first-page":"7579","DOI":"10.1021\/bi201095z","volume":"50","author":"V McParland","year":"2011","unstructured":"McParland V, Varsano G, Li X, Thornton J, Baby J, Aravind A, et al. The metastasis-promoting phosphatase PRL-3 shows activity toward phosphoinositides. Biochemistry. 2011;50:7579\u201390.","journal-title":"Biochemistry"},{"key":"3866_CR30","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1021\/acschembio.6b00570","volume":"11","author":"S Fahs","year":"2016","unstructured":"Fahs S, Lujan P, Kohn M. Approaches to study phosphatases. ACS Chem Biol. 2016;11:2944\u201361.","journal-title":"ACS Chem Biol"},{"key":"3866_CR31","doi-asserted-by":"publisher","first-page":"11882","DOI":"10.1074\/jbc.M312905200","volume":"279","author":"G Kozlov","year":"2004","unstructured":"Kozlov G, Cheng J, Ziomek E, Banville D, Gehring K, Ekiel I. Structural insights into molecular function of the metastasis-associated phosphatase PRL-3. J Biol Chem. 2004;279:11882\u20139.","journal-title":"J Biol Chem"},{"key":"3866_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10127-x","volume":"10","author":"M Thura","year":"2019","unstructured":"Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, Hui KM, et al. PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein. Nat Commun. 2019;10:2484.","journal-title":"Nat Commun"},{"key":"3866_CR33","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1742-4658.2012.08565.x","volume":"280","author":"P Rios","year":"2013","unstructured":"Rios P, Li X, Kohn M. Molecular mechanisms of the PRL phosphatases. FEBS J. 2013;280:505\u201324.","journal-title":"FEBS J"},{"key":"3866_CR34","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2025.09.022","volume":"84","author":"XF Zhang","year":"2026","unstructured":"Zhang XF, Zuo XY, Zhu Y, Li JX, Xian JS, Zhang WX, et al. Targeting cell-state plasticity driven by FOXM1\/CEBPB axis disrupts developmental heterogeneity and therapeutic resistance in hepatocellular carcinoma. J Hepatol. 2026;84:370\u201384.","journal-title":"J Hepatol"},{"key":"3866_CR35","first-page":"198","volume":"18","author":"CY Zhang","year":"2023","unstructured":"Zhang CY, Zhang XF, Yuan J, Gong YF, Tang H, Guo WY, et al. Development and optimization of a human hepatocellular carcinoma patient-derived organoid model for potential target identification and drug discovery. J Vis Exp. 2023;18:198.","journal-title":"J Vis Exp"},{"key":"3866_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-0192-5","volume":"9","author":"M Wei","year":"2020","unstructured":"Wei M, Haney MG, Rivas DR, Blackburn JS. Protein tyrosine phosphatase 4A3 (PTP4A3\/PRL-3) drives migration and progression of T-cell acute lymphoblastic leukemia in vitro and in vivo. Oncogenesis. 2020;9:6.","journal-title":"Oncogenesis"},{"key":"3866_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.tcb.2013.11.002","volume":"24","author":"A Tomas","year":"2014","unstructured":"Tomas A, Futter CE, Eden ER. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol. 2014;24:26\u201334.","journal-title":"Trends Cell Biol"},{"key":"3866_CR38","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/emboj\/16.7.1647","volume":"16","author":"D Graus-Porta","year":"1997","unstructured":"Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997;16:1647\u201355.","journal-title":"EMBO J"},{"key":"3866_CR39","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/annonc\/12.suppl_1.S3","volume":"12","author":"I Rubin","year":"2001","unstructured":"Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol. 2001;12:S3\u20138.","journal-title":"Ann Oncol"},{"key":"3866_CR40","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127\u201337.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3866_CR41","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41421-023-00523-5","volume":"9","author":"X Bai","year":"2023","unstructured":"Bai X, Sun P, Wang X, Long C, Liao S, Dang S, et al. Structure and dynamics of the EGFR\/HER2 heterodimer. Cell Discov. 2023;9:18.","journal-title":"Cell Discov"},{"key":"3866_CR42","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/hmg\/ddm113","volume":"16","author":"AR Mateus","year":"2007","unstructured":"Mateus AR, Seruca R, Machado JC, Keller G, Oliveira MJ, Suriano G, et al. EGFR regulates RhoA-GTP dependent cell motility in E-cadherin mutant cells. Hum Mol Genet. 2007;16:1639\u201347.","journal-title":"Hum Mol Genet"},{"key":"3866_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-0787-y","volume":"14","author":"W Deng","year":"2016","unstructured":"Deng W, Gu L, Li X, Zheng J, Zhang Y, Duan B, et al. CD24 associates with EGFR and supports EGF\/EGFR signaling via RhoA in gastric cancer cells. J Transl Med. 2016;14:32.","journal-title":"J Transl Med"},{"key":"3866_CR44","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/cm.20472","volume":"67","author":"M Amano","year":"2010","unstructured":"Amano M, Nakayama M, Kaibuchi K. Rho-kinase\/ROCK: a key regulator of the cytoskeleton and cell polarity. Cytoskeleton. 2010;67:545\u201354.","journal-title":"Cytoskeleton"},{"key":"3866_CR45","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s12272-019-01153-w","volume":"42","author":"MH Lee","year":"2019","unstructured":"Lee MH, Kundu JK, Chae JI, Shim JH. Targeting ROCK\/LIMK\/cofilin signaling pathway in cancer. Arch Pharm Res. 2019;42:481\u201391.","journal-title":"Arch Pharm Res"},{"key":"3866_CR46","doi-asserted-by":"crossref","unstructured":"May DG, Scott KL, Campos AR, Roux KJ. Comparative application of BioID and TurboID for protein-proximity biotinylation. Cells. 2020;9.","DOI":"10.3390\/cells9051070"},{"key":"3866_CR47","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13046-016-0344-9","volume":"35","author":"B Tang","year":"2016","unstructured":"Tang B, Tang F, Wang Z, Qi G, Liang X, Li B, et al. Overexpression of CTNND1 in hepatocellular carcinoma promotes carcinous characters through activation of Wnt\/beta-catenin signaling. J Exp Clin Cancer Res. 2016;35:82.","journal-title":"J Exp Clin Cancer Res"},{"key":"3866_CR48","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.1038\/s41388-018-0642-0","volume":"38","author":"L Wang","year":"2019","unstructured":"Wang L, Yu T, Li W, Li M, Zuo Q, Zou Q, et al. The miR-29c-KIAA1199 axis regulates gastric cancer migration by binding with WBP11 and PTP4A3. Oncogene. 2019;38:3134\u201350.","journal-title":"Oncogene"},{"key":"3866_CR49","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.molcel.2009.04.034","volume":"34","author":"M Red Brewer","year":"2009","unstructured":"Red Brewer M, Choi SH, Alvarado D, Moravcevic K, Pozzi A, Lemmon MA, et al. The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell. 2009;34:641\u201351.","journal-title":"Mol Cell"},{"key":"3866_CR50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.bbrc.2019.07.126","volume":"518","author":"T Lan","year":"2019","unstructured":"Lan T, Pang J, Wang Z, Wang Y, Qian H, Chen Y, et al. Type II cGMP-dependent protein kinase phosphorylates EGFR at threonine 669 and thereby inhibits its activation. Biochem Biophys Res Commun. 2019;518:14\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"3866_CR51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"DY Oh","year":"2020","unstructured":"Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17:33\u201348.","journal-title":"Nat Rev Clin Oncol"},{"key":"3866_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2020.110267","volume":"192","author":"H Li","year":"2020","unstructured":"Li H, Liu S, Hu Y, Zhao B, Sun Y, Xu D. Endosulfan promotes cell migration via PTP4A3-mediated signaling pathways in HUVECs. Ecotoxicol Environ Saf. 2020;192:110267.","journal-title":"Ecotoxicol Environ Saf"},{"key":"3866_CR53","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1172\/JCI66824","volume":"123","author":"AQ Al-Aidaroos","year":"2013","unstructured":"Al-Aidaroos AQ, Yuen HF, Guo K, Zhang SD, Chung TH, Chng WJ, et al. Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells. J Clin Investig. 2013;123:3459\u201371.","journal-title":"J Clin Investig"},{"key":"3866_CR54","doi-asserted-by":"publisher","first-page":"31202","DOI":"10.1016\/S0021-9258(19)84033-4","volume":"281","author":"J Yong","year":"2006","unstructured":"Yong J, Tan I, Lim L, Leung T. Phosphorylation of myosin phosphatase targeting subunit 3 (MYPT3) and regulation of protein phosphatase 1 by protein kinase A. J Biol Chem. 2006;281:31202\u201311.","journal-title":"J Biol Chem"},{"key":"3866_CR55","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1042\/bj3560257","volume":"356","author":"JA Skinner","year":"2001","unstructured":"Skinner JA, Saltiel AR. Cloning and identification of MYPT3: a prenylatable myosin-targeting subunit of protein phosphatase 1. Biochem J. 2001;356:257\u201367.","journal-title":"Biochem J"},{"key":"3866_CR56","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1006\/bbrc.1998.8291","volume":"244","author":"Q Zeng","year":"1998","unstructured":"Zeng Q, Hong W, Tan YH. Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1. Biochem Biophys Res Commun. 1998;244:421\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"3866_CR57","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1111\/febs.14503","volume":"285","author":"S Hardy","year":"2018","unstructured":"Hardy S, Kostantin E, Hatzihristidis T, Zolotarov Y, Uetani N, Tremblay ML. Physiological and oncogenic roles of the PRL phosphatases. FEBS J. 2018;285:3886\u2013908.","journal-title":"FEBS J"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03866-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03866-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03866-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T22:02:08Z","timestamp":1786399328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03866-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":57,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2026,9,1]]}},"alternative-id":["3866"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03866-x","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"We conformed with the Helsinki Declaration of 1975 (as revised in 2008) concerning Human and Animal Rights, and followed out the policy concerning Informed Consent as shown on Springer.com. All animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee of the Southern University of Science and Technology. The animals were treated in compliance with the relevant institutional and national regulations and guidelines. The number of performing animal experiments is SUSTech-JY202205051. The Committee for Ethical Review of Research Involving Human Subjects at Sun Yat-sen University Cancer Center approved the clinical specimens used in this study (SL-B2024-255-01). All participants provided informed consent.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}